Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAgronomics Regulatory News (ANIC)

Share Price Information for Agronomics (ANIC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 8.15
Bid: 8.10
Ask: 8.20
Change: -0.11 (-1.33%)
Spread: 0.10 (1.235%)
Open: 8.25
High: 8.25
Low: 8.15
Prev. Close: 8.26
ANIC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Agronomics Welcomes Marisa Drew as a Director

23 Feb 2023 07:00

RNS Number : 6296Q
Agronomics Limited
23 February 2023
 

23 February 2023

 

Agronomics Limited

 

("Agronomics" or the "Company")

 

Agronomics Welcomes Marisa Drew to the Board of Directors

Agronomics (ANIC:LSE), the leading listed company focused on the field of cellular agriculture is pleased to announce that it has today appointed Marisa Drew as an Independent Non-Executive Director. Marisa Drew is the inaugural Chief Sustainability Officer ("CSO") of Standard Chartered Bank Plc, responsible for setting the bank's sustainability strategy and the delivery of the firm's commitment to net zero carbon emissions by 2050 as well as overseeing the sustainable finance client-facing activities of the bank. Prior to this, she held the CSO role at Credit Suisse as well as being CEO of the Sustainability Strategy, Advisory & Finance Group. Marisa also Co-Chaired the Sustainability Leaders Committee, served on the ESG Steering Committee, the Climate Risk Strategy Steering Committee, and the UK Reputational Risk Committee of the bank. Marisa also sits on the member of the UK Financial Conduct Authority's Markets Practitioner Panel and has served on several High Level Working Groups ("HLG") sponsored by the World Economic Forum and the UN, including as co-chair of the HLG for Humanitarian Aid and the Oceans Panel.

As a globally recognised leader in sustainability, Marisa brings a vast wealth of experience to the Board and is thoroughly aligned with Agronomics' mission of bringing sustainable alternatives to agricultural products to consumers by investing in leading cellular agriculture companies.

Marisa Drew, Non-Executive Director of Agronomics commented: -

"I am delighted to be joining the Board of Agronomics at this truly exciting time in the field of cellular agriculture. Over the past year, Agronomics has grown its portfolio and is investing in ground-breaking companies and technologies creating a more sustainable protein production system. I look forward to working with my fellow board members to support the growth of the portfolio companies and scaling of the industry."

Jim Mellon, Co-Founder and Executive Director of Agronomics commented: -

"It is a pleasure to welcome Marisa to Agronomics' Board of Directors. Marisa brings with her a wealth of experience, particularly in the sphere of sustainability, and has a track record of achieving investor returns in her previous roles. As a recognised leader in sustainability, Marisa will be well equipped to work with Agronomics' senior team to enhance its portfolio and help advance the prospects for the field of cellular agriculture."

Marisa Danielle Drew (aged 58) is or has during the last five years been a director or partner of the following companies and partnerships:

Current:

Past:

Liberty Global PLC

Sunrise Communications Group AG

Cash & Rocket Holdings Ltd

Aspen Institute UK

 

 

Marisa Drew is also on the Advisory Boards of the Financial Conduct Authority (Expert Markets Practitioners Advisory Panel), The City of London Corporation and Room to Read, an education charity, and was on the Advisory Board at The Wharton School (EMEA Countries Advisory Board) until 2022.

 

Other than as disclosed above, there are no further disclosures to be made in accordance with AIM Rule 17 and paragraph (g) of Schedule Two of the AIM Rules for Companies.

About Agronomics

Agronomics is a leading listed alternative proteins company with a focus on cellular agriculture and cultivated meat. The Company has established a portfolio of over 20 companies in this rapidly advancing sector. It seeks to secure minority stakes in companies owning technologies with defensible intellectual property that offer new ways of producing food and materials with a focus on products historically derived from animals. These technologies are driving a major disruption in agriculture, offering solutions to improve sustainability, as well as addressing human health, animal welfare and environmental damage. This disruption will decouple supply chains from the environment and animals, as well as being fundamental to feeding the world's expanding population. A full list of Agronomics' portfolio companies is available at https://agronomics.im/.

 

About Cellular Agriculture

Cellular Agriculture is the production of agriculture products directly from cells, as opposed to raising an animal for slaughter, or growing crops. This encompasses cell culture to produce cultivated meat and materials, and fermentation processes that harness a combination of molecular biology, synthetic biology, tissue engineering and biotechnology to massively simplify production methods in a sustainable manner.

 

Over the coming decades, the source of the world's food supply traditionally derived from conventional agriculture is going to change dramatically. We have already witnessed the first wave of this shift with the consumer adoption of plant-based alternative proteins but today, we are on the cusp of an even bigger wave of change. This is being facilitated by advances in cellular agriculture. This change is necessary, given scientists claims that if we maintain existing animal protein consumption patterns, then we will not meet the Paris Agreement's goal of limiting warming to 1.5.

 

AT Kearney, a global consultancy firm, projects that cultivated meat's market share will reach 35% by 2040. This combined with the Good Food Institute's estimate that a US $1.8 trillion investment will be required in order to produce just 10% of the world's protein using this technology, means that we are on the cusp of a multi-decade flow of capital to build out manufacturing facilities. Funding in the field of cellular agriculture is accelerating, however still less than US$ 5 billion has been invested worldwide since the industry's inception in 2016.

 

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014, as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

 

For further information please contact:

 

Agronomics

Limited

Beaumont

Cornish Limited

Canaccord

Genuity Limited

Cenkos

Securities Plc

Peterhouse Capital

Limited

 

TB Cardew

The Company

Nomad

Joint Broker

Joint Broker

Joint Broker

Public Relations

Richard Reed

Denham Eke

Roland Cornish

James Biddle

Andrew Potts

Harry Rees

Alex Aylen 

(Head of Equities)

Giles Balleny

Max Gould

Michael Johnson

Lucy Williams

Charles Goodfellow

 Ed Orlebar

Alistair Walker

+44 (0) 1624 639396

info@agronomics.im

+44 (0) 207 628 3396

 

+44 (0) 207 523 8000

+44 (0) 207 397 8900

+44 (0) 207 469 0936

+44 (0) 20 7930 0777

+44 (0) 7738 724 630

agronomics@tbcardew.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCSEWFUFEDSEDE
Date   Source Headline
23rd Dec 201612:00 pmRNSFinal Results and Notice of AGM
22nd Dec 20162:41 pmRNSLoan to the Diabetic Boot Company Ltd
12th Oct 20167:00 amRNSNet Asset Value(s)
22nd Jul 20167:00 amRNSNet Asset Value(s)
29th Apr 20167:00 amRNSNet Asset Value calculation to 31 March 2016
15th Apr 20167:00 amRNSChange of Adviser
18th Mar 20167:00 amRNSHolding(s) in Company
17th Mar 20167:00 amRNSInterim Results for the six months to 31 Dec 2015
10th Feb 201612:11 pmRNSResult of AGM
25th Jan 20167:00 amRNSNet Asset Value(s)
22nd Dec 20157:00 amRNSAnnual Audited Results and Notice of AGM
17th Dec 20154:00 pmRNSDBC receives US FDA approval to market PulseFlowDF
4th Nov 20157:00 amRNSNet Asset Value(s)
30th Jul 20157:01 amRNSNet Asset Value(s)
15th Apr 20157:00 amRNSNet Asset Value as at 31 March 2015
30th Mar 20157:00 amRNSInterim results for 6 months to 31 December 2014
6th Feb 201512:21 pmRNSClose of Tender Offer
4th Feb 20155:36 pmRNSRe Results of Tender Offer
2nd Feb 20158:00 amRNSResults of Tender Offer
23rd Jan 20157:00 amRNSHolding(s) in Company
15th Jan 201511:56 amRNSHolding(s) in Company
14th Jan 20157:00 amRNSTender Offer
12th Jan 20159:32 amRNSNet Asset Value
30th Dec 20147:00 amRNSAnnual audited results
23rd Dec 201411:58 amRNSHolding(s) in Company
28th Nov 20142:04 pmRNSTender Offer in respect of Magna Biopharma
21st Oct 20147:00 amRNSNet Asset Value to 30 September 2014
22nd Jul 20147:00 amRNSNet Asset Value(s)
8th Apr 20147:00 amRNSNet Asset Value calculations to 31 March 2014
31st Mar 20147:00 amRNSInterim Results for the six months to 31 Dec 2013
24th Jan 201411:21 amRNSHolding(s) in Company
20th Jan 201410:56 amRNSHolding(s) in Company
17th Jan 20147:00 amRNSNet Asset Value(s)
15th Jan 20147:00 amRNSAppointment of Nominated Adviser
6th Jan 20145:49 pmRNSHolding(s) in Company
20th Nov 20134:04 pmRNSHolding(s) in Company
13th Nov 20135:13 pmRNSHolding(s) in Company
12th Nov 20137:00 amRNSResult of General Meeting
24th Oct 20137:01 amRNSNotice of General Meeting
24th Oct 20137:00 amRNSAnnual Financial Report
18th Oct 201311:23 amRNSHolding(s) in Company
18th Oct 20137:00 amRNSNet Asset Value(s)
4th Oct 20132:13 pmRNSHolding(s) in Company
26th Sep 20135:10 pmRNSHolding(s) in Company
13th Sep 201311:32 amRNSHolding(s) in Company
6th Sep 20135:29 pmRNSHolding(s) in Company
6th Aug 20139:40 amRNSHolding(s) in Company
11th Jul 20137:00 amRNSNet Asset Value(s)
15th Apr 201312:34 pmRNSDirectorate Change
12th Apr 20132:17 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.